The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies by Aagaard, Lise & Hansen, Ebba Holme
© 2011 Aagaard and Hansen, publisher and licensee Dove Medical Press Ltd.   This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Neuropsychiatric Disease and Treatment 2011:7 729–744
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
729
Review
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S26403
The occurrence of adverse drug reactions 
reported for attention deficit hyperactivity 
disorder (ADHD) medications in the pediatric 
population: a qualitative review of empirical studies
Lise Aagaard1–3
ebba Holme Hansen1–3
1Department of Pharmacology and 
Pharmacotherapy, Section for Social 
Pharmacy, Faculty of Pharmaceutical 
Sciences, University of Copenhagen, 
Denmark; 2FKL-Research Centre for 
Quality in Medicine Use, Copenhagen, 
Denmark; 3Danish Pharmacovigilance 
Research Project (DANPReP), 
Copenhagen, Denmark
Correspondence: Lise Aagaard 
Department of Pharmacology 
and Pharmacotherapy, Faculty of 
Pharmaceutical Sciences, University of 
Copenhagen, Universitetsparken 2,  
2100 Copenhagen, Denmark 
Tel +45 3533 6475 
Fax +45 3530 6001 
email laa@farma.ku.dk
Background: To review empirical studies of adverse drug reactions (ADRs) reported to be 
associated with the use of medications generally licensed for treatment of attention deficit 
hyperactivity disorder (ADHD) symptoms in the pediatric population.
Methods: PubMed, Embase, and PsycINFO® databases were searched from origin until 
June 2011. Studies reporting ADRs from amphetamine derivates, atomoxetine, methylphenidate, 
and modafinil in children from birth to age 17 were included. Information about ADR reporting 
rates, age and gender of the child, type, and seriousness of ADRs, setting, study design, ADR 
assessors, authors, and funding sources were extracted.
Results: The review identified 43 studies reporting ADRs associated with medicines for 
treatment of ADHD in clinical studies covering approximately 7000 children, the majority 
of 6- to 12-year-old boys, and particularly in the United States of America (USA). The most 
frequently reported ADRs were decrease in appetite, gastrointestinal pain, and headache. There 
were wide variations in reported ADR   occurrence between studies of similar design, setting, 
included population, and type of medication. Reported ADRs were primarily assessed by the 
children/their parents, and very few ADRs were rated as being serious. A large number of children 
dropped out of studies due to serious ADRs, and therefore, the actual number of serious ADRs 
from use of psychostimulants is probably higher. A large number of studies were conducted 
by the same groups of authors and sponsored by the pharmaceutical companies manufacturing 
the respective medications.
Conclusion: Reported ADRs from use of psychostimulants in children were found in clinical 
trials of short duration. Since ADHD medications are prescribed for long-term treatment, there is 
a need for long-term safety studies. The pharmaceutical companies should make all information 
about ADRs reported for these medications accessible to the public, and further studies are needed 
on the impact of the link between researchers and the manufacturers of the respective products.
Keywords: adverse drug reactions, attention deficit hyperactivity disorder, children, pharmaco-
vigilance
Introduction
Psychostimulants, such as amphetamine derivates, methylphenidate, and modafinil, as 
well as the nonstimulant medication atomoxetine, are considered first-line medication 
treatment of attention deficit hyperactivity disorder (ADHD) symptoms in the pediatric 
population.1 Case reports on serious cardiovascular adverse drug reactions (ADRs), 
sudden death, and psychiatric disorders led regulatory agencies to warn against the use Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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of methylphenidate in the pediatric population in 2006 and 
2007.2,3 In 2006, warnings were also linked to atomoxetine 
use due to reports of hepatotoxicity and suicidal thoughts in 
children.4 Concern has been raised about ADRs from long-
term treatment with ADHD medications, such as psychosis, 
sensitization, dependency, and withdrawal reactions.1 The 
issue of appropriate warnings about possible ADRs to the 
use of methylphenidate and other ADHD medications is ever 
more important as usage continues to increase rapidly in 
many countries: an increase in the number of treated patients 
has been observed, as well as an increase in the average 
dispensed daily dose of psychostimulants.5
The use of psychostimulants, particularly methylpheni-
date, to treat ADHD symptoms in children has increased rap-
idly since the 1990s. Studies have shown that the   prevalence 
of psychostimulant use in children in the   Netherlands 
increased eight times from 1996 to 2006,6 and in Germany, 
prescription rates of methylphenidate increased by 96% 
from 2000 to 2007.7 From 1994 to 2004, the prevalence 
of psychostimulant use in Norwegian children increased 
five times,8 while the prevalence of stimulant medication 
increased ten times in American children from 1987 to 1996.9 
Previous meta-analyses and reviews that evaluated the short-
term efficacy of psychostimulants on ADHD symptoms in 
children concluded that psychostimulants are more effective 
than placebo with respect to treating disturbed attention and 
impulsivity.1,10 Several articles have reported information 
about the safety of methylphenidate and other psycho-
stimulants in clinical studies,11 but to the current reviewers’ 
knowledge no articles have systematically reviewed the 
occurrence of ADRs following the use of ADHD medications 
in the pediatric population.
The objective of this study is to review published 
empirical studies on the occurrence of adverse drug reactions 
(ADRs) associated with the use of medications generally 
licensed for treatment of ADHD symptoms in the pediatric 
population.
Methods
Literature search
A literature search was performed in PubMed, Embase, and 
PsycINFO® (whole databases without language   restriction) 
using the search terms “atomoxetine” (ATC group 
N06BA09), “methylphenidate” (ATC group N06BA04), 
“modafinil” (ATC group N06BA07), “amphetamine” (ATC 
group N06BA02), “psychostimulants,” and “nonstimulants” 
combined with any of the following: “adverse drug 
  reaction,” “side effect,” and “adverse event.” Reference 
lists of identified articles were also screened for additional 
potentially relevant articles. For further details of the search 
strategy, please see Appendix 1. Literature searches were 
updated until September 2011.
Study selection
Using article titles as the selection basis, the first author 
retrieved and screened the abstracts to identify studies 
relevant to the study objective. Potentially relevant articles 
were retrieved in full text and screened for inclusion. To be 
considered relevant for this review, articles had to be peer 
reviewed and report ADRs in children in the age group 0–17 
years of age associated with the use of psychostimulants.
Psychostimulants were specified as amphetamine deri-
vates, methylphenidate, and modafinil, and nonstimulants as 
atomoxetine. Articles reporting ADRs from psychostimulants 
in mixed populations of children and adults were excluded 
if age-related ADR occurrence was not specified. Articles 
were excluded if they did not report data on ADR occurrence 
that made it possible to calculate rates. Hence, case reports, 
letters, commentaries, interim analyses, meta-analyses, and 
review articles were excluded. Further, articles reporting 
unintended events not classified as ADRs and articles on 
misuse were excluded, although reference lists of these 
studies were searched for relevant studies.
Data extraction
Data from included articles were extracted using a standard 
form, one for each article. The following information was 
recorded: authors, publication year, country, study design, 
dosage, comparator, monitoring period (weeks), size of 
study population, age and gender of included population, 
and ADR reporting rates in percentage. ADR reporting rates 
were indicated as reported in the original papers. In placebo-
controlled studies, information about ADR reporting rates 
for placebo was also extracted. Information about who had 
assessed the ADRs, reported ADRs classified as being serious 
by the respective authors, and funding sources were also 
recorded. The first author extracted data, while the second 
author controlled and verified all cases.
Results
A total of 137 potentially relevant references were identified dur-
ing the database searches and reference screenings. An overview 
of the review process and reasons for exclusion are displayed 
in Figure 1. Sixty-eight studies were excluded after screening 
abstracts. Sixty-nine studies were retrieved for full text review. 
Of these studies, four were later excluded as they reported mixed Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Articles retrieved for more detailed evaluation  
(N = 69) 
Potentially relevant articles identified and 
screened for retrieval (N = 137)  Excluded studies (N = 68)  
Commentaries (N = 8) 
Efficacy studies without information about ADRs (N = 28) 
Doublets (N = 25)  
Case reports (N = 7) 
Excluded studies (N = 26)*  
Studies with a mixture of adults and children (N = 4) 
Meta-analysis (N = 8) 
Reviews (N = 4) 
Subgroup analysis (N = 2) 
Results shown as % of children reporting ADRs (N = 8) 
Articles included in the review  
 (N = 43) 
Figure 1 Decision tree of the review process.
Note: *An overview of excluded studies is shown in Appendix 2.
Abbreviation: ADRs, adverse drug reactions. 
data on children and adults that could not be separated. Eight 
meta-analyses and four reviews of efficacy were excluded as 
they reported information from studies already included. Also 
excluded were two studies reporting data from a subgroup 
analysis of already included studies, and nine studies reporting 
ADRs as percent of children reporting an ADR.
Eventually 43 articles reporting ADRs from psycho-
stimulants in the pediatric population were included. Table 1 
displays an overview of the study characteristics of included 
articles. The majority of studies were conducted in the United 
States of America (USA), the remaining in Australia, Canada, 
Europe, Iran, and Latin America. Atomoxetine studies were 
published in the period from 2001 to 2009; amphetamine 
studies from 1997 to 2007; methylphenidate studies from 
1997 to 2009; and modafinil studies from 2005 to 2009.
Design and setting
Information about ADRs was reported in clinical   studies 
using different designs, ie, randomized parallel group 
  studies (N = 28);12–15,17–19,22,23,28,31,32,34–36,40,42–47,48–54 random-
ized crossover studies (N = 6);16,23,25,27,30,39 and open-label 
designs (N = 9).20,26,29,33,37,38,41,50 The majority of studies were 
conducted in naturalistic settings at home and at school   
(N = 38);12,13,15–22,24,26,28–30,31–43,44–54 five articles reported 
ADRs from children participating in laboratory school 
protocols,14,23,25,27,30 in which classroom sessions were orga-
nized in cycles to include 12 hours of observation. This 
design consisted of daily schedules of alternating classroom, 
meals/snacks, recess, and research activities scheduled 
at specific times during the day. The largest number of 
studies (N = 21)31–47 concerned atomoxetine; followed by 
methylphenidate (N = 14;17–30 modafinil (N = 7);48–54 and 
amphetamine (N = 5).12–16
Dosage and comparator
The tested dosages varied from 10 to 70 mg/day in amphet-
amine studies; from 5 to 72 mg/day in methylphenidate 
studies; from 10 to 90 mg/day in atomoxetine studies; and 
from 100 to 425 mg/day in modafinil studies. Placebo was 
used as a comparator drug in the majority of studies (N = 28), 
while an active comparator, was administered in nine studies. 
Seven open-label studies did not include a control group.
Treatment period
Treatment duration varied from 1 to 32 weeks across studies. 
Treatment duration varied from 2 to 4 weeks in amphetamine Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 1 Characteristics of included studies by country, design, study population, and funding
Studies 
(chronological order)
Country Design Setting Dosage  
(mg/day)
Comparator Treatment 
weeks (N)
Patients  
included (N)
Patients 
completed (N)
Age (y) % Male Type of  
assessor
Funding
Amphetamine
Biederman et al12 USA R parallel Naturalistic 30–70 Placebo 4 290 218 6–12 69 Parent industry
Spencer et al13 USA R parallel Naturalistic 10–40 Placebo 4 335 308 6–17 69 Parent industry
wigal et al14 USA R parallel Laboratory 10–30 Atomoxetine 3 102 93 6–12 75 Parent industry
Biederman et al15 USA R parallel Naturalistic 10–30 Placebo 3 374 336 6–12 80 Parent industry
efron et al16 AU R crossover Naturalistic 0.15 mg/kg MPH 2 125 121 5–15 91 Teacher/Parent Nonindustry
Total/Range 2–4 1226 1076 5–17 69–91
Methylphenidate
Arabgol et al17 iR R parallel Naturalistic 20–50 Reboxetine 6 16 12 7–16 66 Teacher/Parent Nonindustry
Maayan et al20 USA Open label Naturalistic 10–30 NR 4 14 11 4–5 82 Self NR
Amiri et al49 iR R parallel Naturalistic 20–30 Modafinil 6 32 30 6–15 80 Teacher/Parent Nonindustry
Findling et al18 USA R parallel Naturalistic 10–54 Placebo 7 189 137 6–12 65 Self industry
Newcorn et al19 USA R parallel Naturalistic 18–54 Atomoxetine 6 220 180 6–16 71 Parent industry
Findling et al21 various R parallel Naturalistic 10–60 Placebo 3 272 240 6–12 80 Self industry
Greenhill et al22 USA R parallel Naturalistic 5–30 Placebo 7 53 48 6–17 59 Self industry
McGough et al23 USA R crossover Laboratory 10–27 Placebo 5 42 41 6–12 73 Self industry
Gau et al24 Tw R open label Naturalistic 10–40 None 4 64 64 6–15 91 Self industry
Silva et al25 USA R crossover Laboratory 20–40 Placebo ,1 54 53 6–12 70 Parent industry
Kemner et al26 USA R open label Naturalistic 18–72 Atomoxetine 3 891 850 6–12 74 Parent industry
Swanson et al27 USA R crossover Laboratory 18–60 Placebo NR 184 181 6–12 74 Self/Parent industry
Biederman et al28 USA/CA R parallel Naturalistic 10–40 Placebo 2 65 61 6–14 80 Parent industry
Kratochvil et al29 USA/CA R open label Naturalistic 5–60 None 10 44 25 7–15 100 Parent industry
Pelham et al30 USA R crossover Lab/Nat 5–54 Placebo 3 70 68 6–12 NR Teacher/Parent industry
efron et al16 AU R crossover Naturalistic 0.3 mg/kg Amphetamine 2 125 121 5–15 91 Teacher/Parent Nonindustry
Total/Range 1–10 2303 2092 4–17 59–100
Atomoxetine
Svanborg et al31 Se R parallel Naturalistic 80 Placebo 10 49 49 7–15 80 Self industry
Block et al32 USA R parallel Naturalistic 0.47–1.81 mg/kg Placebo 6 288 140 6–12 73 Parent industry
Tamayo et al33 various Open label Naturalistic 35–120 None 10–11 1198 947 6–17 76 Self industry
Newcorn et al19 USA R parallel Naturalistic 0.8–1.8 mg/kg MPH/Placebo 6 222 186 6–16 78 Parent industry
Bangs et al34 US R parallel Naturalistic 1.2–1.8 mg/kg Placebo 9 72 71 12–17 72 Self industry
Geller et al35 USA R parallel Naturalistic 0.8–1.8 mg/kg Placebo 12 87 66 8–17 62 Self industry
Gau et al36 Tw R parallel Naturalistic 16–99 Placebo 6 72 72 6–16 90 Parent industry
Kratochvil et al37 USA Open label Naturalistic 0.5–1.8 mg/kg None 8 22 20 5–6 86 Parent industry
Prasad et al38 UK R open label Naturalistic 0.5–1.8 mg/kg SCT 10 104 78 7–15 89 Self industry
Arnold et al39 USA R cross over Naturalistic 2.5–40 Placebo 12 16 15 5–15 75 Self industry
Newcorn et al40 USA R parallel Naturalistic 1.2–1.8 mg/kg None 32 229 160 6–16 72 Parent industry
wigal et al14 USA R parallel Laboratory 10–60 Amphetamine 3 101 97 6–12 76 Parent industry
Allen et al42 USA R parallel Naturalistic 0.5–1.5 mg/kg Placebo 18 76 74 7–17 92 Self industry
Kemner et al26 USA R open label Naturalistic 10–80 MPH 3 499 473 6–12 74 Parent industry
escobar et al41 eS Open label Naturalistic 0.5–1.8 mg/kg None 10 36 36 6–15 89 Parent industry
Kelsey et al43 USA R parallel Naturalistic 0.8–1.2 mg/kg Placebo 8 133 107 6–12 71 Parent industry
Biederman et al44 USA R parallel Naturalistic 2 mg/kg Placebo 9 31 31 7–13 0 Self industry
Michelson et al45 USA R parallel Naturalistic 0.5–1.0 mg/kg Placebo 6 85 84 6–16 71 Parent industry
Kratochvil et al29 USA/CA R open label Naturalistic 0.2–2.0 mg/kg None 10 184 118 7–15 91 Parent industry
Spencer et al46 USA R parallel Naturalistic 90 Placebo 12 129 127 7–13 76 Parent industry
Michelson et al47 USA R parallel Naturalistic 0.5–1.8 mg/kg Placebo 8 213 176 8–17 71 Self industry
Total/Range 3–32 3846 3127 5–17 0–91
Modafinil
Kahbazi et al48 iR R parallel Naturalistic 200–300 Placebo 6 24 23 6–15 76 Teacher/Parent Nonindustry
Amiri et al49 iR R parallel Naturalistic 200–300 MPH 6 32 30 6–15 78 Teacher/Parent Nonindustry
Boellner et al50 USA Open label Naturalistic 100–400 None 8 220 166 6–14 72 Parent industry
wigal et al51 USA R parallel Naturalistic 170–425 Placebo 9 423 411 10.2 72 Parent/Self industry
Biederman et al52 USA R parallel Naturalistic 300–400 Placebo 4 197 175 6–14 75 Parent industry
Greenhill et al53 USA R parallel Naturalistic 170–425 Placebo 9 133 100 6–16 73 Parent/Self industry
Biederman et al54 USA R parallel Naturalistic 170–425 Placebo 9 164 97 6–17 69 Parent industry
Total/Range 4–9 1137 949 6–17 69–75
Total all studies 8512 7244 – –
Abbreviations: AU, Australia; CA, Canada; iR, iran; lab, laboratory; MPH, methylphenidate; nat, naturalistic; NR, not reported; R, randomized; eS, Spain; SCT, standard 
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Table 1 Characteristics of included studies by country, design, study population, and funding
Studies 
(chronological order)
Country Design Setting Dosage  
(mg/day)
Comparator Treatment 
weeks (N)
Patients  
included (N)
Patients 
completed (N)
Age (y) % Male Type of  
assessor
Funding
Amphetamine
Biederman et al12 USA R parallel Naturalistic 30–70 Placebo 4 290 218 6–12 69 Parent industry
Spencer et al13 USA R parallel Naturalistic 10–40 Placebo 4 335 308 6–17 69 Parent industry
wigal et al14 USA R parallel Laboratory 10–30 Atomoxetine 3 102 93 6–12 75 Parent industry
Biederman et al15 USA R parallel Naturalistic 10–30 Placebo 3 374 336 6–12 80 Parent industry
efron et al16 AU R crossover Naturalistic 0.15 mg/kg MPH 2 125 121 5–15 91 Teacher/Parent Nonindustry
Total/Range 2–4 1226 1076 5–17 69–91
Methylphenidate
Arabgol et al17 iR R parallel Naturalistic 20–50 Reboxetine 6 16 12 7–16 66 Teacher/Parent Nonindustry
Maayan et al20 USA Open label Naturalistic 10–30 NR 4 14 11 4–5 82 Self NR
Amiri et al49 iR R parallel Naturalistic 20–30 Modafinil 6 32 30 6–15 80 Teacher/Parent Nonindustry
Findling et al18 USA R parallel Naturalistic 10–54 Placebo 7 189 137 6–12 65 Self industry
Newcorn et al19 USA R parallel Naturalistic 18–54 Atomoxetine 6 220 180 6–16 71 Parent industry
Findling et al21 various R parallel Naturalistic 10–60 Placebo 3 272 240 6–12 80 Self industry
Greenhill et al22 USA R parallel Naturalistic 5–30 Placebo 7 53 48 6–17 59 Self industry
McGough et al23 USA R crossover Laboratory 10–27 Placebo 5 42 41 6–12 73 Self industry
Gau et al24 Tw R open label Naturalistic 10–40 None 4 64 64 6–15 91 Self industry
Silva et al25 USA R crossover Laboratory 20–40 Placebo ,1 54 53 6–12 70 Parent industry
Kemner et al26 USA R open label Naturalistic 18–72 Atomoxetine 3 891 850 6–12 74 Parent industry
Swanson et al27 USA R crossover Laboratory 18–60 Placebo NR 184 181 6–12 74 Self/Parent industry
Biederman et al28 USA/CA R parallel Naturalistic 10–40 Placebo 2 65 61 6–14 80 Parent industry
Kratochvil et al29 USA/CA R open label Naturalistic 5–60 None 10 44 25 7–15 100 Parent industry
Pelham et al30 USA R crossover Lab/Nat 5–54 Placebo 3 70 68 6–12 NR Teacher/Parent industry
efron et al16 AU R crossover Naturalistic 0.3 mg/kg Amphetamine 2 125 121 5–15 91 Teacher/Parent Nonindustry
Total/Range 1–10 2303 2092 4–17 59–100
Atomoxetine
Svanborg et al31 Se R parallel Naturalistic 80 Placebo 10 49 49 7–15 80 Self industry
Block et al32 USA R parallel Naturalistic 0.47–1.81 mg/kg Placebo 6 288 140 6–12 73 Parent industry
Tamayo et al33 various Open label Naturalistic 35–120 None 10–11 1198 947 6–17 76 Self industry
Newcorn et al19 USA R parallel Naturalistic 0.8–1.8 mg/kg MPH/Placebo 6 222 186 6–16 78 Parent industry
Bangs et al34 US R parallel Naturalistic 1.2–1.8 mg/kg Placebo 9 72 71 12–17 72 Self industry
Geller et al35 USA R parallel Naturalistic 0.8–1.8 mg/kg Placebo 12 87 66 8–17 62 Self industry
Gau et al36 Tw R parallel Naturalistic 16–99 Placebo 6 72 72 6–16 90 Parent industry
Kratochvil et al37 USA Open label Naturalistic 0.5–1.8 mg/kg None 8 22 20 5–6 86 Parent industry
Prasad et al38 UK R open label Naturalistic 0.5–1.8 mg/kg SCT 10 104 78 7–15 89 Self industry
Arnold et al39 USA R cross over Naturalistic 2.5–40 Placebo 12 16 15 5–15 75 Self industry
Newcorn et al40 USA R parallel Naturalistic 1.2–1.8 mg/kg None 32 229 160 6–16 72 Parent industry
wigal et al14 USA R parallel Laboratory 10–60 Amphetamine 3 101 97 6–12 76 Parent industry
Allen et al42 USA R parallel Naturalistic 0.5–1.5 mg/kg Placebo 18 76 74 7–17 92 Self industry
Kemner et al26 USA R open label Naturalistic 10–80 MPH 3 499 473 6–12 74 Parent industry
escobar et al41 eS Open label Naturalistic 0.5–1.8 mg/kg None 10 36 36 6–15 89 Parent industry
Kelsey et al43 USA R parallel Naturalistic 0.8–1.2 mg/kg Placebo 8 133 107 6–12 71 Parent industry
Biederman et al44 USA R parallel Naturalistic 2 mg/kg Placebo 9 31 31 7–13 0 Self industry
Michelson et al45 USA R parallel Naturalistic 0.5–1.0 mg/kg Placebo 6 85 84 6–16 71 Parent industry
Kratochvil et al29 USA/CA R open label Naturalistic 0.2–2.0 mg/kg None 10 184 118 7–15 91 Parent industry
Spencer et al46 USA R parallel Naturalistic 90 Placebo 12 129 127 7–13 76 Parent industry
Michelson et al47 USA R parallel Naturalistic 0.5–1.8 mg/kg Placebo 8 213 176 8–17 71 Self industry
Total/Range 3–32 3846 3127 5–17 0–91
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Kahbazi et al48 iR R parallel Naturalistic 200–300 Placebo 6 24 23 6–15 76 Teacher/Parent Nonindustry
Amiri et al49 iR R parallel Naturalistic 200–300 MPH 6 32 30 6–15 78 Teacher/Parent Nonindustry
Boellner et al50 USA Open label Naturalistic 100–400 None 8 220 166 6–14 72 Parent industry
wigal et al51 USA R parallel Naturalistic 170–425 Placebo 9 423 411 10.2 72 Parent/Self industry
Biederman et al52 USA R parallel Naturalistic 300–400 Placebo 4 197 175 6–14 75 Parent industry
Greenhill et al53 USA R parallel Naturalistic 170–425 Placebo 9 133 100 6–16 73 Parent/Self industry
Biederman et al54 USA R parallel Naturalistic 170–425 Placebo 9 164 97 6–17 69 Parent industry
Total/Range 4–9 1137 949 6–17 69–75
Total all studies 8512 7244 – –
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studies; from 1 to 10 weeks in methylphenidate studies; from 
3 to 32 weeks in atomoxetine studies; and from 4 to 9 weeks 
in modafinil studies.
Population
A total of 8512 children were included in the clinical 
studies, of which 7244 children completed treatment: 
amphetamine (1076); methylphenidate (2092); atomoxetine 
(3127); and modafinil (949). The reasons for noncomple-
tion were many, but lack of efficacy and the appearance of 
ADRs were the most common. The ages of the included 
children varied from 4 to 17 years (median 6–12 years), 
and the share of male patients in the studies varied from 0 
to 100% (median 69%).
Type of assessor
Parents rated information about ADRs in 20 studies,12–15,19,25–28, 
32,35–36,40–46,48,50,52 54 patients in 15 studies,18,20–24,31,33–35,38–39,42,44,47 
and a combination of teacher/parent (five studies),16–17,30,48–49 
and patient/parent (three studies).27,49,51 The articles specified 
only limited information about applied ADR scales and the 
classification systems used.
Funding source
In almost all studies the funding source was the manufacturer 
of the respective medications, and only four studies were 
publicly funded. Additionally, a large number of the studies 
were conducted by the same groups of authors who declared 
conflicts of interest. The majority of the authors received 
contributions from the pharmaceutical companies producing 
the medications in return for activities, such as providing 
scientific advice and making oral and poster presentations 
at scientific meetings.
ADRs by type and occurrence
Tables 2–5 display the ADR reporting rates listed in the 
included studies for each type of psychostimulant. ADRs 
of similar type and wording were aggregated in a common 
category in order to clarify data presentation. The aggre-
gated categories were: weight changes (changes in weight, 
weight decreased, weight increased, decrease in weight); 
gastrointestinal pain (abdominal pain, upper abdominal 
pain, gastrointestinal pain); anxiety (anxiety, anxiousness); 
influenza (influenza, flu syndrome); tics (tics, motor tics, 
facial tics); blood pressure changes (diastolic blood pressure, 
changes in blood pressure); sleeping problems (awake dur-
ing the night, difficulty falling asleep, sleep disturbance, 
delayed onset of sleep); changes in heart rate (racing heart, 
changes in heart rate). Thirty-one categories of ADRs were 
reported for amphetamine derivates (Table 2); 65 categories 
for methylphenidate formulations (Table 3); 55 categories 
for atomoxetine (Table 4); and 38 categories for modafinil 
(Table 5). The following ADRs were most frequently reported 
for all four psychostimulants: decrease in appetite, gastroin-
testinal pain, and headache.
ADRs by seriousness
The majority of reported ADRs were categorized by the 
authors/investigators as nonserious. Table 6 shows informa-
tion about the categories of serious ADRs reported in the 
clinical studies. Serious cases included aggression (amphet-
amine, methylphenidate);16 anxiety (amphetamine);16 
emotional disturbances (amphetamine);14,15 insomnia 
Table 2 Adverse drug reaction reporting rates (%) for amphetamine 
derivates by category and study
Reference number 12 13 14 15 16 Range Placebo   
(range)
Adverse drug reaction
Accidental injury – 5 – – – 5 5
Anorexia – 25 17 22 – 17–25 2
Anxiety – – – – 68 68 –
Appetite decrease 39 – 28 – 59 28–59 4–5
Cough 1 – – 5 – 1–5 5
Crying – – – – 76 76 –
Daydreams – – – – 62 62 –
Dizziness 5 – 6 – 32 5–32 –
Dry mouth 5 – – – – 5 –
emotional disturbance – – – – 59 59 –
emotional lability – 5 – 9 – 5–9 2
Fatigue – – 2 – – 2 –
Fingernail biting – – – – 40 40 –
Gastrointestinal pain 12 11 19 14 – 11–19 5–10
Headache 12 19 15 18 30 12–30 10–21
insomnia 19 20 28 17 – 17–28 2–8
irritability 10 – 7 – 82 7–82 –
Nasal congestion 1 – – – – 1 –
Nasopharyngitis 5 – – – – 5 –
Nausea 6 – 7 5 – 5–7 3
Nervousness – 6 – 6 – 6 2
Nightmares – – – – 28 28 –
Pharyngitis – 7 – 7 – 7 5–20
Sleeping problems – – – – 70 70 –
Social withdrawal – – – – 64 64 –
Somnolence – – 5 – – 5 –
Stomachache – – – – 40 40 –
Tics – – – – 26 26 –
Unusually happy – – – – 26 26 –
vomiting 9 – 5 7 – 5–9 4
weight changes 9 8 6 – – 6–9 1Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Table 3 Adverse drug reaction reporting rates (%) for methylphendiate by category and study
Reference number 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 49 Range Placebo   
(range)
Adverse drug reaction
Abnormal behavior – – – – – 3 – – – – 1 – – 5 – – 1–5 4
Accidental injury – – – – – – – – – – – 3 – 13 3 – 3–13 3
Affect lability – – 3 – – – 4 – – – – – – – – – 3–4 –
Aggression – – – – – – – – – – 1 – – – – – 1 –
Anorexia – – 3 – – 5 4 3 – 8 – 3 3 15 – – 3–15 1–2
Anxiety 61 – – – – – – – 25 – – – – – – 5 5–61 1
Appetite decrease 56 31 19 17 28 3 30 – 53 9 6 3 – – – 31 3–56 5–9
Asthenia – – – – – – – – – – – – – 3 – – 3 –
Blood pressure changes – – – 18 – – – 3 – – – – – – – – 3–18 –
Changes in heart rate – – – 12 – – – – – – – – – – – – 12 –
Changes in pulse rate – – – – – – – – – 1 – – – – – – 1 –
Chest pain – 6 – – – – – – – – – – – – – – 6 –
Cough – – – 4 – 2 – – – – – – – 5 – – 2–5 4
Crying 71 – – – – – – – 38 – 2 – – – – – 2–71 –
Daydreams 62 – – – – – – – 30 – – – – – – – 30–62 –
Depression – – – – – – – – – – – – – 5 – – 5 –
Diarrhea – – – – – – 4 – – – – – – 3 2 – 2–4 1–2
Dizziness 30 13 – – – – – – 13 – 1 – – – 2 – 1–30 4
Dry mouth – – – – – – – – 24 – – – – – – 12 12–24 –
Dyspepsia – – – – – – 8 – – – – – – 5 – – 5–8 –
emotional disturbance 56 – – – – – – – – – 1 – – – – – 1–56 –
emotional lability – – – – 8 – – – – – – – – 5 – 7 5–8 –
euphoria – – – – – – – – 9 – – – – – – – 9 –
eye redness – – – – 4 – – – – – – – – – – – 4 –
eye twitching – – – – 4 – – – – – – – – – – – 4 –
Fatigue – – – 2 4 – 4 – – 4 1 – – – – – 1–4 4
Fever – – – – 4 2 – – – – – – – 10 – – 2–10 7
Fingerrnail biting 45 – – – – – – – 22 – – – – – – – 22–45 –
Gastroenteritis – – – – – – 4 – – – – 5 – – – – 4–5 4
Gastrointestinal pain – – – 10 12 10 19 – – 6 4 4 – 18 15 8 4–19 2–13
Headache 24 – – 11 4 16 25 4 28 2 4 3 2 33 14 8 2–33 3–23
Hyperkinesia – – – – – – – – – – – – – 5 – – 5 –
increases in ALT/AST – – – – – – – – – – – 5 – – – – 5 –
infection – – – – 4 – – – – – – 2 – 8 – – 2–8 1–4
Influenza – – – – – – 4 – – – – – – 10 – – 4–10 –
insomnia – 19 8 27 – 4 8 – 44 4 7 2 3 18 – – 2–44 3–10
irritability 80 6 – 6 4 3 4 – 16 – 1 1 – – – 7 1–80 2–6
Lymphadenopathy – – – – – – – 3 – – – – – – – – 3 –
Mood alteration – – – – – – – – 34 – 1 7 – – – – 1–34 –
Nasal congestion – – 3 – 4 – – – – – – – – – – – 3–4 1
Nasopharyngitis – – 4 – – 4 9 1 – – – – – – – – 1–9 2–7
Nausea – – 8 6 – – 11 4 – – 1 – – 5 – 5 1–11 2–6
Nervousness – – – – – – – – – – – 4 – 10 – – 4–10 –
Nightmare 21 – – – – – – – 16 – – – – – – – 16–21 –
Otitis media – – – – – – 4 – – – – – – – – – 4 2
Pain – – – – – – – – – – – – – 3 – – 3 –
Pallor – 13 – – – – – – – – – – – – – – 13 –
Palpitation – – – – – – – – – – – – – 5 – – 5 –
Pharyngeal pain – – – – – – – 3 – – – – – – – – 3 –
Pharyngitis – – – – – 3 – – – – – – – 8 2 – 2–8 3
Rash – – – – – – – 1 – – – – – 8 – – 1–8 4
Respiratory tract infection – – – – – 3 9 – – – – – – – 4 – 3–9 2–6
Rhinitis – – – – – – – 3 – – – – – 20 2 – 2–20 –
Sensitivity – – – – 4 – – – – – – – – – – – 4 –
Sleeping problems 64 – – – 12 – – – – – – – – – – 9 9–64 –
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(amphetamine, modafinil);13,15,37 and attempted suicide 
(amphetamine).13
Discussion
This is the first study to systematically review the empirical 
literature on the occurrence of ADRs reported for ADHD 
medications in the pediatric population.   Information 
about ADRs from psychostimulants and the nonstimu-
lant atomoxetine was reported in clinical studies of short 
duration, primarily conducted in 6- to 12-year-old boys, 
and particularly in the USA. The most frequently reported 
ADRs were decrease in appetite, gastrointestinal pain, 
and headache. A large number of studies were conducted 
by the same groups of authors and sponsored by the 
pharmaceutical companies manufacturing the respective 
medications.
Design and setting
Although the review process found a large number of small 
clinical trials exploring the efficacy of ADHD medications 
in the pediatic population, only a minor share of these stud-
ies reported information about ADRs. The studies included 
in this article were similar in design and setting, treatment 
duration, as well as number, age, and gender of included 
patients. The reliability of the studies may be questioned as 
the number of reported ADRs varied widely for identical and 
similar study designs. Further exploration of these questions 
would require access to the original study material. Large 
variations in ADR reporting rates were observed between 
studies and therapeutic groups, and similar types of ADRs 
were reported for the individual ADHD medications. It is 
puzzling that large numbers of specific ADRs are reported 
in some studies, but few if any in others. These findings 
question the relevance of the many small clinical trials 
conducted on the medications, particularly atomoxetine 
and methylphenidate, as they are not designed to measure 
long-term efficacy and safety.55 Almost all of these clinical 
trials were sponsored by the pharmaceutical companies 
producing the subject medications, and therefore, the current 
reviewers encourage these companies to make information 
about the ADRs reported in said clinical trials accessible 
to the public.
Seriousness of reported ADRs
Only a small number of serious ADRs were reported. 
However, in several of the included studies a large num-
ber of children withdrew due to experiencing ADRs, and 
therefore, the actual number of serious ADRs occurring 
from the use of ADHD medications might be higher, and 
some types of ADRs may not have been reported. Informa-
tion about ADR incidence in the monitored population was 
only reported if the incidence was above 2% and/or 5%; 
consequently, information about rarely occurring ADRs is 
not included. Another issue is that information about defi-
nitions and scales to define and evaluate events occurring 
during the clinical trials is not reported in the articles, thus 
making it impossible to react to this information. Therefore, 
the regulatory agencies are encouraged to allow access 
to the original clinical protocols, so that all information 
reported for ADHD medications can be made public. 
A previous study has shown that there are large discrepan-
cies between the data reported in clinical trial protocols and 
data published in scientific journals.56
Long-term safety aspects of 
psychostimulant use
Psychostimulants and other ADHD medications are pre-
scribed for long-term treatment in large populations and 
Table 3 (Continued)
Reference number 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 49 Range Placebo   
(range)
Socially withdrawn 59 – – – – – – – 27 – – – – – – – 27–59 –
Somnolence – – – 2 – – – – – – 1 – – – – – 1–2 –
Stomachache 32 – – – – – 4 – 28 – – – – – – – 4–32 –
Tachycardia – – – – – – – – – – – – – 5 – – 5 –
Tics 28 – 1 – – – – – 13 – – – – – – – 1–28 4
Twitching – – – – – – – – – – – – – – 3 – 3 –
Unusually happy 28 – – – – – – – – – – – – – – – 28 –
Urinary incontinence – – – – – – – – – – – – – – 1 – 1 3
vomiting – – 10 4 4 3 4 – – – 1 1 – – 3 – 1–10 2–5
weight changes – – 8 1 – – – – – – – – – 5 – 8 1–8 4
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there is a need for long-term efficacy and safety studies.1 
The lack of sufficient knowledge about ADRs at the point 
of licensing of new medicines makes spontaneous ADR 
reporting an important source of information about medi-
cine safety.57 As clinical trials in the pediatric population 
are limited, clinicians and health authorities must rely 
on spontaneous reports as the main source of information 
about previously unknown ADRs.57 However, the current 
review did not find any studies about ADRs from the use 
of psychostimulants reported to any national ADR data-
bases. Systematic analyses of ADRs reported to national 
databases are necessary, as these databases constitute a 
critical (and underestimated) source of important data, 
especially information about new, serious, and rarely occur-
ring ADRs. Further studies of data from large databases, ie, 
the World Health Organization/Uppsala Monitoring Centre 
VigiBase™ (Uppsala, Sweden) or the European Medicines 
Agency EudraVigilance (London, United Kingdom [UK]) 
databases, are recommended in order to increase knowledge 
about ADRs from the use of ADHD medications.
Strengths and limitations of this review
The included studies were conducted over a period of 
approximately 20 years in different countries, with a great 
deal of inconsistency in observing and classifying the type 
and seriousness of reported ADRs. Information about 
the seriousness of the reported ADRs was extracted from 
the included studies, and it was not possible for the review 
to evaluate these ratings, nor to estimate ADRs in terms of 
effect sizes, as the review did not have access to the original 
data material. A major limitation of this study is that it is 
unknown to what extent the causality of these ADRs can be 
confirmed, and this has implications for the interpretation 
of the findings in the review. A large number of published 
clinical studies were not included in this review because these 
articles did not report information about ADRs, despite the 
fact that pharmaceutical companies had a legal obligation 
to monitor ADRs in clinical trials, and therefore, these data 
must exist. As the clinical trials were mainly sponsored by the 
pharmaceutical companies that produce the medications, 
these companies are urged to make these data accessible to 
the public.
Conclusion
Reported ADRs from the use of psychostimulants in the 
pediatric population were generally found in clinical trials 
of short duration. Since ADHD medications are prescribed 
for long-term treatment there is a need for long-term safety Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
739
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Table  6  Serious  ADRs  reported  for  ADHD  medications  in 
identified studies
Medication  
(alphabetically)
Reference Adverse drug reaction(s)
Amphetamine Spencer et al13 Arthrosis 
Hyperkinesia 
insomnia 
Nervousness 
Pharyngitis 
Suicide attempt
wigal et al14 emotional disturbance 
Headache
Biedermann et al15 Anorexia 
emotional lability 
insomnia
efron et al16 Agitation 
Aggression 
Anxiety
Methylphenidate efron et al16 Aggression 
Headache 
Tearful
Greenhill et al22 Hypersomnia
Kemner et al26 Mania
Biederman et al28 Depression
Atomoxetine wigal et al14 Upper abdominal pain
Arnold et al39 Aggression
Modafinil Boellner et al50 
Biederman et al52
insomnia 
insomnia
wigal et al51 Asthma 
Dehydration 
Duodenitis 
erythema multiforme 
Hypertonia 
Influenza syndrome 
Peptic ulcer 
Stevens–Johnson syndrome
Abbreviations: ADRs, adverse drug reactions; ADHD, attention deficit hyperactivity 
disorder.
Authors’ contributions
LA and EHH designed the study, analyzed the data, and 
wrote the final draft of the manuscript. LA conducted the 
literature search and data extraction. EHH checked all data 
extractions. Both authors read and approved the final version 
of the manuscript.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  American Academy of Pediatrics. Clinical practice guideline: treatment 
of the school-aged child with attention-deficit/hyperactivity disorder. 
Pediatrics. 2001;108(4):1033–1044.
  2.  European Medicines Agency. Meeting Highlights From the Committee 
for Medicinal Products for Human Use, 16–19 July 2007. Doc. Ref. 
EMEA/431407/2007. London: European Medicines Agency; 2007. 
  Available from: http://www.ema.europa.eu/docs/en_GB/document_library/
Press_release/2009/12/WC500017068.pdf. Accessed October 31, 2011.
  3.  Novartis Pharmaceuticals Corporation, United States Food and Drug 
Administration. Ritalin®, Ritalin-SR®. East Hanover, New Jersey: 
Novartis Pharmaceuticals Corporation; 2007. Available from: http://
www.accessdata.fda.gov/drugsatfda_docs/label/2007/010187s069,01
8029s040,021284s011lbl.pdf. Accessed October 31, 2011.
  4.  Mosholder AD. Overview of ADHD and its pharmacotherapy. 
  Gaithersburg, MD: United States Food and Drug Administration, Drug 
Safety and Risk Management Advisory Committee; February 9, 2006. 
Available from: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006–
4202S1_01_FDA-mosholder.ppt. Accessed July 18, 2011.
  5.  Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for 
management of attention-deficit/hyperactivity disorder in adolescents 
and in adults: recommendations from the British Association for 
  Psychopharmacology. J Psychopharmacol. 2007;21(1):10–41.
  6.  Trip AM, Visser ST, Kalverdijk LJ. Large increase of the use of psycho-
stimulants among youth in The Netherlands between 1996 and 2006. 
Br J Clin Pharmacol. 2009;67(4):466–468.
  7.  Schubert I, Köster I, Lehmkuhl G. The changing prevalence of attention-
deficit/hyperactivity disorder and methylphenidate prescriptions: a study 
of data from a random sample of insurees of the AOK Health Insurance 
Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int. 
2010;107(36):615–621.
  8.  Asheim H, Nilsen KB, Johansen K, et al. Forskvivning av sentralstimul-
erende legemidler ved AD/HD i Nordland [Prescribing of stimulants 
for ADHD in Nordland County]. Tidsskr Nor Laegeforen. 2007;127: 
2360–2362. Article in Norwegian.
  9.  Zuvekas SH, Vitiello B, Norquist GS. Recent trends in the stimulant medica-
tion use among US children. Am J Psychiatry. 2006;163(4):579–585.
 10.  Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: 
  treatment of attention-deficit/hyperactivity disorder in children with comorbid 
tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48(9):884–893.
  11.  Aagaard L, Thirstrup S, Hansen EH. Opening the white boxes: the licens-
ing documentation of efficacy and safety of psychotropic medicines for 
children. Pharmacoepidemiol Drug Saf. 2009;18(5):401–411.
  12.  Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lis-
dexamfetamine dimesylate (NRP-104) in children with attention-deficit/
hyperactivity disorder: a phase III, multicenter, randomized, double-blind, 
forced-dose, parallel-group study. Clin Ther. 2007;29(3):450–463.
  13.  Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed 
amphetamine salts extended release (Adderall XR) in the management 
of oppositional defiant disorder with or without comorbid attention-
deficit/hyperactivity disorder in school-aged children and adolescents: a 
4-week, multicenter, randomized, double-blind, parallel-group, placebo-
  controlled, forced-dose-escalation study. Clin Ther. 2006;28:402–418.
studies. Considering the widespread and increasing use of 
these medications in children, greater care must be taken 
when prescribing these medications for long-term use. 
  Further studies of spontaneous reports submitted to national 
and international databases are recommended in order to 
increase knowledge about ADRs from the use of psychostim-
ulants in the pediatric population. Pharmaceutical companies 
should make all information about ADRs reported for ADHD 
medications accessible to the public. Additionally, the impact 
of the link between researchers and the manufacturers of the 
medications needs to be studied.
Acknowledgments
We wish to thank Ditte Sloth-Lisbjerg, MSc (Pharm.), 
for assistance with parts of the literature search and data 
extraction.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
741
Review of adverse reactions for ADHD medication in children
  14.  Wigal SB, McGough JJ, McCracken et al. A laboratory school 
comparison  of  mixed  amphetamine  salts  extended  release 
(Adderall XR) and atomoxetine (Strattera) in school-aged children 
with attention deficit/hyperactivity disorder. J Atten Disord. 2005;9(1): 
275–289.
  15.  Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-
blind, placebo-controlled, parallel-group study of SLI381 (Adderall 
XR) in children with attention-deficit/hyperactivity disorder. Pediatrics. 
2002;110(2):258–266.
  16.  Efron D, Jarman F, Barker M. Side effects of methylphenidate and 
dexamphetamine in children with attention deficit hyperactivity 
disorder: a double-blind, crossover trial. Pediatrics. 1997;100(4): 
662–666.
  17.  Arabgol F, Panaghi L, Hebrani P. Reboxetine versus methylphenidate in 
treatment of children and adolescents with attention deficit-hyperactivity 
disorder. Eur Child Adolesc Psychiatry. 2009;18(1):53–59.
  18.  Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-
blind, placebo-controlled, parallel-group study of methylphenidate trans-
dermal system in pediatric patients with attention-deficit/hyperactivity 
disorder. J Clin Psychiatry. 2008;69(1):149–159.
  19.  Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmoti-
cally released methylphenidate for the treatment of attention deficit 
hyperactivity disorder: acute comparison and differential response. 
Am J Psychiatry. 2008;165(6):721–730.
  20.  Maayan L, Paykina N, Fried J, et al. The open-label treatment of 
attention-deficit/hyperactivity disorder in 4- and 5-year-old children 
with beaded methylphenidate. J Child Adolesc Psychopharmacol. 
2009;19(2):147–153.
  21.  Findling R, Quinn D, Hatch SJ, et al. Comparison of the clinical effi-
cacy of twice-daily Ritalin and once-daily Equasym XL with placebo 
in children with Attention-Deficit/Hyperactivity Disorder. Eur Child 
Adolesc Psychiatry. 2006;15(8):450–459.
  22.  Greenhill LL, Muniz R, Ball RR, et al. Efficacy and safety of dexm-
ethylphenidate extended-release capsules in children with attention-
deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 
2006;45(7):817–823.
  23.  McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, 
placebo-controlled, laboratory classroom assessment of methylpheni-
date transdermal system in children with ADHD. J Atten Disord. 
2006;9(3):476–485.
  24.  Gau SS, Shen HY, Soong WT, et al. An open-label, randomized, active-
controlled equivalent trial of osmotic release oral system methylpheni-
date in children with attention-deficit/hyperactivity disorder in Taiwan. 
J Child Adolesc Psychopharmacol. 2006;16(4):441–455.
  25.  Silva RR, Muniz R, Pestreich L, et al. Efficacy and duration of effect 
of extended-release dexmethylphenidate versus placebo in school-
children with attention-deficit/hyperactivity disorder. J Child Adolesc 
  Psychopharmacol. 2006;16(3):293–251.
  26.  Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS 
methylphenidate compared with atomoxetine in children with 
ADHD: a multicenter, randomized prospective study. Adv Ther. 
2005;22(5):498–512.
  27.  Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily 
extended-release methylphenidate formulations in children with 
attention-deficit/hyperactivity disorder in the laboratory school (the 
Comacs Study). Pediatrics. 2004;113(3 Pt 1):e206–e216.
  28.  Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, 
a new, once daily, extended-release dosage form of methylphenidate, in 
children with attention deficit hyperactivity disorder. Paediatr Drugs. 
2003;5(12):833–841.
  29.  Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and 
methylphenidate treatment in children with ADHD: a prospective, 
randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 
2002;41(7):776–784.
  30.  Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day 
  Concerta methylphenidate versus three-times-daily methylphenidate 
in laboratory and natural settings. Pediatrics. 2001;107(6):e105.
  31.  Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety if 
atomoxetine as add-on to psychoeducation in the treatment of attention 
deficit/hyperactivity disorder: a randomized, double-blind, placebo-
controlled study in stimulant-naïve Swedish children and adolescents. 
Eur Child Adolesc Psychiatry. 2009;18(4):240–249.
  32.  Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating 
pediatric attention-deficit/hyperactivity disorder: comparison of morn-
ing and evening dosing. Clin Pediatr (Phila). 2009;48(7):723–733.
  33.  Tamayo JM, Pumariega A, Rothe EM, et al. Latino versus Caucasian 
response to atomoxetine in attention-deficit/hyperactivity disorder. 
J Child Adolesc Psychopharmacol. 2008;18(1):44–53.
  34.  Bangs ME, Emslie GJ, et al, (Atomoxetine ADHD and Comorbid MDD 
Study Group). Efficacy and safety of atomoxetine in adolescents with 
attention-deficit/hyperactivity disorder and major depression. J Child 
Adolesc Psychopharmacol. 2007;17(4):407–420.
  35.  Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for 
pediatric patients with attention-deficit/hyperactivity disorder with 
comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 
2007;46(9):1119–1127.
  36.  Gau SF, Huang YS, Soong WT, et al. A randomized, double-blind, 
  placebo-controlled clinical trial on once-daily atomoxetine hydrochloride 
in Taiwanese children and adolescents with attention-deficit/hyperactiv-
ity disorder. J Child Adolesc Psychopharmacol. 2007;17:4:447–461.
  37.  Kratochvil CJ, Vaughan BS, Mayfield-Jorgensen ML, et al. A pilot study 
of atomoxetine in young children with attention-deficit/hyperactivity 
disorder. J Child Adolesc Psychopharmacol. 2007;17(2):175–185.
  38.  Prasad S, Harpin V , Poole L, et al. A multi-centre, randomized, open-
label study of atomoxetine compared with standard current therapy 
in UK children and adolescents with attention-deficit/hyperactivity 
disorder (ADHD). Curr Med Res Opin. 2007;23(2):379–394.
  39.  Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity 
in autism spectrum disorders: placebo-controlled crossover pilot trial. 
J Am Acad Child Adolesc Psychiatry. 2006;45(10):1196–1205.
  40.  Newcorn JH, Michelson D, Kratochvil CJ, et al. Low-dose atomoxetine 
for maintenance treatment of attention-deficit/hyperactivity disorder. 
Pediatrics. 2006;118(6):e1701–e1706.
  41.  Escobar R, Soutullo C, San Sebastián J, et al. Atomoxetine safety 
and efficacy in children with attention deficit/hyperactivity disorder 
(ADHD): initial phase of 10-week treatment in a relapse prevention 
study with a Spanish sample. Actas Esp Psiquiatr. 2004;33(1):26–32. 
Article in Spanish.
  42.  Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in 
children and adolescents with ADHD and comorbid tic disorders. 
Neurology. 2005;65(12):1941–1949.
  43.  Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine 
treatment for children with attention-deficit/hyperactivity disorder, 
including an assessment of evening and morning behavior: a double-
blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1–e8.
  44.  Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine 
versus placebo in school-aged girls with attention-deficit/hyperactivity 
disorder. Pediatrics. 2002;110(6):e75.
  45.  Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treat-
ment for children and adolescents with attention deficit hyperactivity 
disorder: a randomized, placebo-controlled study. Am J Psychiatry. 
2002;159(11):1896–1901.
  46.  Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 
proof-of-concept, placebo-controlled studies of atomoxetine in chil-
dren with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 
2002;63(12):1140–1147.
  47.  Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment 
of children and adolescents with attention-deficit/hyperactivity disorder: 
a randomized, placebo-controlled, dose-response study. Pediatrics. 
2001;108(5):e83.
  48.  Kahbazi M, Ghoreishi A, Rahiminejad F, et al. A randomized, double-
blind and placebo-controlled trial of modafinil in children and adoles-
cents with attention deficit and hyperactivity disorder. Psychiatry Res. 
2009;168(3):234–237.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
742
Aagaard and Hansen
  49.  Amiri S, Mohammadi MR, Mohamaddi M, et al. Modafinil as treat-
ment for Attention-Deficit/Hyperactivity Disorder in children and 
adolescents: a double blind, randomized clinical trial. Prog Neuropsy-
chopharmacol Biol Psychiatry. 2008;32(1):145–149.
  50.  Boellner S, Earl CQ, Arora S. Modafinil in children and adolescents 
with attention-deficit/hyperactivity disorder: a preliminary 8-week, 
open-label study. Curr Med Res Opin. 2006;22(12):2457–2465.
  51.  Wigal SB, Biederman J, Swanson JM, et al. Efficacy and safety of 
modafinil film-coated tablets in children and adolescents with or without 
prior stimulant treatment for attention-deficit/hyperactivity disorder: 
pooled analysis of 3 randomized, double-blind, placebo-controlled 
  studies. Prim Care Companion J Clin Psychiatry. 2006;8(6):352–360.
  52.  Biederman J, Swanson JM, Wigal SB, et al. A comparison of once-daily 
and divided doses of modafinil in children with attention-deficit/hyper-
activity disorder: a randomized, double-blind, and placebo-controlled 
study. J Clin Psychiatry. 2006;67(5):727–735.
  53.  Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-
blind, placebo-controlled study of modafinil film-coated tablets in 
children and adolescents with attention-deficit/hyperactivity disorder. 
J Am Acad Child Adolesc Psychiatry. 2006;45(5):503–511.
  54.  Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety 
of modafinil film-coated tablets in children and adolescents with 
attention-deficit/hyperactivity disorder: results of a randomized, 
double-blind, placebo-controlled, flexible-dose study. Pediatrics. 
2005;116(6):e777–e784.
  55.  Hansen EH. Technology assessment in a user perspective – experi-
ences with drug technology. Int J Technol Assess Health Care. 
1992;8(1):150–165.
  56.  Gøtzsche P, Hróbjartsson A, Johansen HK, et al. Constraints 
on publication rights in industry-initiated clinical trials. JAMA. 
2006;295(14):1645–1646.
  57.  Aagaard L, Hansen EH. Information about ADRs explored by pharma-
covigilance approaches: a qualitative review of studies on antibiotics, 
SSRIs, and NSAIDs. BMC Clin Pharmacol. 2009;9:4.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
743
Review of adverse reactions for ADHD medication in children
Appendix 2
excluded studies listed by reason for 
exclusion, alphabetically by first author
Meta-analyses
Bangs ME, Tauscher-Wisniewski S, Polzer J, et al.   Meta-analysis 
of suicide-related behavior events in patients treated 
with atomoxetine. J Am Acad Child Adolesc   Psychiatry. 
2008;47(2):209–218.
Greenhill LL, Newcorn JH, Gao H, et al. Effect of two dif-
ferent methods of initiating atomoxetine on the adverse 
event profile of atomoxetine. J Am Acad Child Adolesc 
Psychiatry. 2007;46(5):566–572.
Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of 
long-term atomoxetine treatment for young children with 
attention-deficit/hyperactivity disorder. J Am Acad Child 
Adolesc Psychiatry. 2006;45(8):919–927.
Kratochvil CJ, Michelson D, Newcorn JH, et al. High-dose 
atomoxetine treatment of ADHD in youths with limited 
response to standard doses. J Am Acad Child Adolesc 
  Psychiatry. 2007;46(9):1128–1137.
Kratochvil CJ, Milton DR, Vaughan BS, et al. Acute ato-
moxetine treatment of younger and older children with 
ADHD: a meta-analysis of tolerability and efficacy. Child 
Adolesc Psychiatry Ment Health. 2008;2(1):25.
Polzer J, Bangs ME, Zhang S, et al. Meta-analysis of 
aggression or hostility events in randomized, controlled 
clinical trials of atomoxetine for ADHD. Biol Psychiatry. 
2007;61(5):713–719.
Schachter HM, Pham B, King J, et al. How efficacious and 
safe is short-acting methylphenidate for the treatment of 
attention-deficit disorder in children and adolescents? A 
  meta-analysis. CMAJ. 2001;165(11):1475–1488.
Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term ato-
moxetine treatment in adolescents with attention-deficit/
hyperactivity disorder. J Pediatr. 2006;149(1):112–119.
Review articles
Brams M, Moon E, Pucci M, et al. Duration of effect of oral 
long-acting stimulant medications for ADHD throughout 
the day. Curr Med Res Opin. 2010;26(8):1809–1825.
Findling RL. Evolution of the treatment of attention-deficit/
hyperactivity disorder in children: a review. Clin Ther. 
2008;30(5):942–957.
Merkel RL Jr, Kuchibhatla A. Safety of stimulant treatment 
in attention deficit hyperactivity disorder: Part I. Expert 
Opinion Drug Saf. 2009;8(6):655–668.
Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects 
of atomoxetine in children, adolescents, and adults. Drug 
Saf. 2003;26(10):729–740.
Studies with a mixture of adults and children/
adolescents
Bangs ME, Jin L, Zhang S, et al. Hepatic events associated 
with atomoxetine treatment for attention-deficit hyperac-
tivity disorder. Drug Saf. 2008;31(4):345–354.
Maia CR, Matte BC, Ludwig HT, et al. Switching from 
methylphenidate immediate release to MPH-SODAS in 
attention-deficit/hyperactivity disorder. Eur Child Adolesc 
Psychiatry. 2008;17(3):133–142.
Paterson R, Douglas C, Hallmayer J, et al. A randomised, 
double-blind, placebo-controlled trial of dexamphetamine 
in adults with attention deficit hyperactivity disorder. Aust 
N Z J Psychiatry. 1999;33(4):494–502.
Appendix 1 
Search strategy: complete databases were 
searched until February 2011
embase
  Adverse event
  Methylphenidate
  Adverse drug reaction AND methylphenidate
  (Adverse event OR adverse drug reaction) AND psychostimulant
  Atomoxetine OR modafinil OR methylphenidate OR amphetamine
    (Atomoxetine OR modafinil OR methylphenidate OR amphetamine) 
AND adverse event
PubMed
  Adverse event
  Methylphenidate
  Adverse event AND methylphenidate
  Adverse event OR adverse drug reaction
  Psychostimulant
  (Adverse event OR adverse effect) AND psychostimulant
  Atomoxetine OR modafinil OR methylphenidate OR amphetamine
    (Atomoxetine OR modafinil OR methylphenidate OR amphetamine) 
AND adverse event
PsyciNFO®
  Adverse event
  Methylphenidate
  Adverse event AND methylphenidate
  Side effect
  Adverse drug reaction
  Psychostimulant
  (Adverse drug reaction OR side effect) AND psychostimulant
  Adverse drug reaction OR side effect OR adverse event
  Atomoxetine OR modafinil OR methylphenidate OR amphetamine
    (Adverse event OR side effect OR adverse drug reaction) AND 
(Atomoxetine OR modafinil OR methylphenidate OR amphetamine)Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS.   
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
744
Aagaard and Hansen
Pelham WE, Gnagy EM, Chronis AM, et al. A comparison 
of morning-only and morning/late afternoon Adderall 
to morning-only, twice-daily, and three times-daily 
methylphenidate in children with attention-deficit/hyper-
activity disorder. Pediatrics. 1999;104(6):1300–1311.
Pelham WE Jr, Greenslade KE, Vodde-Hamilton M, et al. 
Relative efficacy of long-acting stimulants on children 
with attention deficit-hyperactivity disorder: a com-
parison of standard methylphenidate, sustained-release 
methylphendiate, sustained-release dextroamphetamine 
and pemoline. Pediatrics. 1990;86(2):226–237.
Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of 
Ritalin and Adderall: efficacy and time-course in children 
with attention-deficit/hyperactivity disorder. Pediatrics. 
1999;103(4):e43.
Rugino TA, Copley TC. Effects of modafinil in children 
with attention-deficit/hyperactivity disorder: an open-
label study. J Am Acad Child Adolesc Psychiatry. 
2001;40(2):230–235.
Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-
coated tablets in children and adolescents with attention-
deficit/hyperactivity disorder: results of a randomized, 
double-blind, placebo-controlled, fixed-dose study 
followed by abrupt discontinuation. J Clin Psychiatry. 
2006;67(1):137–147.
Wernicke JF, Holdridge KC, Jin L, et al. Seizure risk in 
patients with attention-deficit-hyperactivity disorder 
treated with atomoxetine. Dev Med Child Neurol. 
2007;49(7):498–502.
Sub-group analyses of clinical studies
Durell TM, Pumariega AJ, Rothe EM, et al. Effects of open-
label atomoxetine on African-American and Caucasian 
pediatric outpatients with attention-deficit/hyperactivity 
disorder. Ann Clin Psychiatry. 2009;21(1):26–37.
Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine 
treatment of ADHD in children with comorbid Tourette 
syndrome. J Atten Disord. 2008;11(4):470–481.
ADRs presented as number of children reporting 
ADRs, assessment of rate not possible
Davari-Ashtiani R, Shahrbabaki ME, Razjouyan K, et al. 
  Buspirone versus methylphenidate in the treatment of 
attention deficit hyperactivity disorder: a double-blind 
and randomized trial. Child Psychiatry Hum Dev. 
2010;41(8):641–648.
Barkley RA, McMurray MB, Edelbrock CS, et al. Side effects 
of methylphenidate in children with attention deficit 
hyperactivity disorder: a systemic, placebo-controlled 
  evaluation. Pediatrics. 1990;86(2):184–192.
Firestone P, Musten LM, Pisterman S, et al. Short-term side 
effects of stimulant medication are increased in preschool 
children with attention-deficit/hyperactivity disorder: a 
double-blind placebo-controlled study. J Child Adolesc 
Psychopharmacol. 1998;8(1):13–25.